Cargando…

Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019

Lack of age-appropriate commercially drug products availability is a common problem in pediatric therapeutics; this population needs improved and safer drug delivery. In addition, biopharmaceutic aspects, dosage requirements, and swallowing abilities demand pediatric forms different to adult formula...

Descripción completa

Detalles Bibliográficos
Autores principales:	delMoral-Sanchez, Jose-Manuel, Gonzalez-Alvarez, Isabel, Gonzalez-Alvarez, Marta, Navarro-Ruiz, Andres, Bermejo, Marival
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238124/ https://www.ncbi.nlm.nih.gov/pubmed/32244848 http://dx.doi.org/10.3390/pharmaceutics12040316

Ejemplares similares

Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System
por: delMoral-Sanchez, Jose-Manuel, et al.
Publicado: (2019)

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
por: Thor, Shannon, et al.
Publicado: (2023)

First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization
por: Fortner, Andra, et al.
Publicado: (2021)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Using the WHO Essential Medicines List to Assess the Appropriateness of Insurance Coverage Decisions: A Case Study of the Croatian National Medicine Reimbursement List
por: Jeličić Kadić, Antonia, et al.
Publicado: (2014)

EMA issues recommendations on impurities in medicines
Publicado: (2020)

Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
por: Husain, Muhammad Jami, et al.
Publicado: (2020)

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines
por: Mustafa, Asma Abubakr, et al.
Publicado: (2010)

Monographs for medicines on WHO’s Model List of Essential Medicines
por: Roth, Lukas, et al.
Publicado: (2018)

Correction to: Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
Publicado: (2020)

Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Brain Levels of Drug in Rat
por: Sánchez-Dengra, Bárbara, et al.
Publicado: (2021)

New In Vitro Methodology for Kinetics Distribution Prediction in the Brain. An Additional Step towards an Animal-Free Approach
por: Sánchez-Dengra, Bárbara, et al.
Publicado: (2021)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Withdrawn medicines included in the essential medicines lists of 136 countries
por: Charles, Onella, et al.
Publicado: (2019)

Biologic medicine inclusion in 138 national essential medicines lists
por: Kraus, Raphaël, et al.
Publicado: (2021)

Cost Analysis of Different Antibiotic Brands Available in Indian Market with Reference to National List of Essential Medicines
por: Meena, Dinesh Kumar, et al.
Publicado: (2021)

Essential tuberculosis medicines and health outcomes in countries with a national essential medicines list
por: Maraj, Darshanand, et al.
Publicado: (2022)

Comparison of essential medicines lists in 137 countries
por: Persaud, Nav, et al.
Publicado: (2019)

The case for levetiracetam to be included in essential medicine lists
por: Singh, Gagandeep, et al.
Publicado: (2023)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
por: Malottki, Kinga, et al.
Publicado: (2011)

Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists
por: Jarvis, Jordan D., et al.
Publicado: (2019)

Establishment and Validation of a New Co-Culture for the Evaluation of the Permeability through the Blood–Brain Barrier in Patients with Glioblastoma
por: Sánchez-Dengra, Bárbara, et al.
Publicado: (2023)

Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List
por: Gotham, Dzintars, et al.
Publicado: (2019)

The FDA initiatives for personalized medicine
por: Wolfe, Olive Joy
Publicado: (2014)

National List of Essential Medicines, 2015: Endocrinology perspective
por: Kalra, Sanjay
Publicado: (2016)

A comparison of national essential medicines lists in the Americas
por: Steiner, Liane, et al.
Publicado: (2020)

Revising the WHO Essential Medicines List for paediatric rheumatology
por: Scott, Christiaan, et al.
Publicado: (2021)

Indian Essential Medicine List for Children: Time to Revisit
por: Singhal, Shubha, et al.
Publicado: (2023)

Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018)
por: Seo, Yurim, et al.
Publicado: (2020)

Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women
por: Alidjanov, Jakhongir F., et al.
Publicado: (2019)

EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations
por: Boesen, Kim, et al.
Publicado: (2021)

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
por: Hanaizi, Zahra, et al.
Publicado: (2022)

Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS
por: Kang, Su Lim, et al.
Publicado: (2023)

Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
por: Zheng, Fangfang, et al.
Publicado: (2018)

Availability, prices and affordability of essential medicines in Haiti
por: Chahal, Harinder Singh, et al.
Publicado: (2013)

Availability of Essential Medicines for Pediatric Oncology in Armenia
por: Simonyan, Tamara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lfa9lnj0t8rknp7guclol0abqi